177 related articles for article (PubMed ID: 20558855)
1. Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations.
Chen Z; Huo JR
Neth J Med; 2010 Jun; 68(6):252-60. PubMed ID: 20558855
[TBL] [Abstract][Full Text] [Related]
2. Hepatic veno-occlusive disease as a result of a traditional remedy: confirmation of toxic pyrrolizidine alkaloids as the cause, using an in vitro technique.
Zuckerman M; Steenkamp V; Stewart MJ
J Clin Pathol; 2002 Sep; 55(9):676-9. PubMed ID: 12194997
[TBL] [Abstract][Full Text] [Related]
3. Tusanqi and hepatic sinusoidal obstruction syndrome.
Wang JY; Gao H
J Dig Dis; 2014 Mar; 15(3):105-7. PubMed ID: 24528632
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation.
Iguchi A; Kobayashi R; Yoshida M; Kobayashi K; Matsuo K; Kitajima I; Maruyama I
Bone Marrow Transplant; 2001 Jun; 27(11):1173-80. PubMed ID: 11551028
[TBL] [Abstract][Full Text] [Related]
5. Hepatic veno-occlusive disease induced by Gymura segetum: report of two cases.
Dai HF; Gao Y; Yang M; Yu CH; Gu ZY; Chen WX
Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):406-8. PubMed ID: 16911940
[TBL] [Abstract][Full Text] [Related]
6. Veno-occlusive disease in a fetus caused by pyrrolizidine alkaloids of food origin.
Rasenack R; Müller C; Kleinschmidt M; Rasenack J; Wiedenfeld H
Fetal Diagn Ther; 2003; 18(4):223-5. PubMed ID: 12835579
[TBL] [Abstract][Full Text] [Related]
7. Post-transplant hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment.
Ho V; Momtaz P; Didas C; Wadleigh M; Richardson P
Rev Clin Exp Hematol; 2004 Jun; 8(1):E3. PubMed ID: 16029969
[TBL] [Abstract][Full Text] [Related]
8. [Veno-occlusive liver disease due to intake of Senecio vulgaris tea].
Ortiz Cansado A; Crespo Valadés E; Morales Blanco P; Sáenz de Santamaría J; González Campillejo JM; Ruiz Téllez T
Gastroenterol Hepatol; 1995 Oct; 18(8):413-6. PubMed ID: 7584780
[TBL] [Abstract][Full Text] [Related]
9. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation.
Kumar S; DeLeve LD; Kamath PS; Tefferi A
Mayo Clin Proc; 2003 May; 78(5):589-98. PubMed ID: 12744547
[TBL] [Abstract][Full Text] [Related]
10. [Sinusoidal obstruction disease (SOS), previous hepatic venoocclusive disease (VOD)--still serious complication after hematopoietic stem cell transplantation].
Gozdzik J; Krasowska-Kwiecień A; Wedrychowicz A
Przegl Lek; 2008; 65(4):203-8. PubMed ID: 18724548
[TBL] [Abstract][Full Text] [Related]
11. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids.
Gao H; Li N; Wang JY; Zhang SC; Lin G
J Dig Dis; 2012 Jan; 13(1):33-9. PubMed ID: 22188914
[TBL] [Abstract][Full Text] [Related]
12. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
[TBL] [Abstract][Full Text] [Related]
13. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome.
Gao H; Ruan JQ; Chen J; Li N; Ke CQ; Ye Y; Lin G; Wang JY
Drug Des Devel Ther; 2015; 9():4861-8. PubMed ID: 26346783
[TBL] [Abstract][Full Text] [Related]
14. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation.
Toh HC; McAfee SL; Sackstein R; Cox BF; Colby C; Spitzer TR
Bone Marrow Transplant; 1999 Oct; 24(8):891-5. PubMed ID: 10516702
[TBL] [Abstract][Full Text] [Related]
15. [Hepatic veno-occlusive disease associated with ingestion of Senecio tephrosioides].
Tomioka M; Calvo F; Siguas A; Sánchez L; Nava E; García U; Valdivia M; Reátegui E
Rev Gastroenterol Peru; 1995; 15(3):299-302. PubMed ID: 8580460
[TBL] [Abstract][Full Text] [Related]
16. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years.
Kalayoglu-Besisik S; Yenerel MN; Caliskan Y; Ozturk S; Besisik F; Sargin D
Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400
[TBL] [Abstract][Full Text] [Related]
17. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
[TBL] [Abstract][Full Text] [Related]
18. Protein C and procollagen III peptide levels in patients with hepatic dysfunction after allogeneic hematopoietic stem cell transplantation.
Pihusch M; Wegner H; Goehring P; Salat C; Pihusch V; Andreesen R; Kolb HJ; Holler E; Pihusch R
Bone Marrow Transplant; 2005 Oct; 36(7):631-7. PubMed ID: 16062176
[TBL] [Abstract][Full Text] [Related]
19. [Hepatotoxicity of medicinal plants and plant-based preparations].
Pauwels A; Mostefa-Kara N
Gastroenterol Clin Biol; 1993; 17(5 Pt 2):H79-85. PubMed ID: 8243922
[No Abstract] [Full Text] [Related]
20. The veno-occlusive disease of the liver.
Baron F; Deprez M; Beguin Y
Haematologica; 1997; 82(6):718-25. PubMed ID: 9499675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
